Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease
2015 IASLC World Conference on Lung CancerKaren Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).
Related Videos
Alice T. Shaw, MD, PhD, on ALK, Crizotinib, and Alectinib
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–s...
Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial
Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of...
Guneet Walia, PhD, on Central Issues in Lung Cancer Care
Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance ther...
Eric Lim, MD, on Increasing Incidence of Non-Smoking Lung Cancer
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more impo...
Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07)...
